Liquidia Technologies

Yahoo Finance • 10 days ago

Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s Why

Liquidia Corporation (NASDAQ:LQDA) is one of the best high growth healthcare stocks to buy now. Wells Fargo raised the price target on Liquidia Corporation (NASDAQ:LQDA) to $51 from $44 on March 23, reiterating an Overweight rating on the... Full story

Yahoo Finance • 13 days ago

The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M

Liquidia(NASDAQ:LQDA) Chief Commercial Officer Scott Moomaw reported the exercise and immediate sale of 80,000 shares of common stock, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 80,000 Transac... Full story

Yahoo Finance • 27 days ago

Mid-Cap healthcare stocks ranked by quant ratings after earnings season

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of co... Full story

Yahoo Finance • 29 days ago

Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart

On February 17, 2026, Findell Capital Management disclosed a buy of 32,000 shares of Dave(NASDAQ:DAVE) in the fourth quarter, with the estimated transaction value at $6.88 million based on the quarterly average price. What happened Accor... Full story

Yahoo Finance • last month

United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says

United Therapeutics (UTHR) remains a "top pick" due to several near- to medium-term catalysts that c PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Liquidia GAAP EPS of $0.15 misses by $0.05, revenue of $92.02M beats by $4.53M

* Liquidia press release [https://seekingalpha.com/pr/20425170-liquidia-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides] (LQDA [https://seekingalpha.com/symbol/LQDA]): Q4 GAAP EPS of $0.15 misses by $... Full story

Yahoo Finance • last month

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story

Yahoo Finance • last month

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story

Yahoo Finance • 2 months ago

Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside. On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estima... Full story

Yahoo Finance • 2 months ago

Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling

Arquitos Capital Partners, an investment management firm, released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Arquitos Capital Management reported a standout year in which the fund returned 82.1% net of fees... Full story

Yahoo Finance • 4 months ago

Arquitos Capital Management’s Updates on Liquidia Corporation (LQDA)

Arquitos Capital Management, an investment management firm, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the third quarter, the fund delivered a net return of 29.6% bringing year-to-d... Full story

Yahoo Finance • 4 months ago

This Small-Cap Consumer Stock Has Landed New Institutional Backing as Shares Surge 60%

Key Points New York City-based Findell Capital Management added 90,000 shares of Turning Point Brands for an estimated $8.9 million in the third quarter. The move marked a new position for Findell, which reported holding no shares of Turn... Full story

Yahoo Finance • 5 months ago

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of t... Full story

Yahoo Finance • 5 months ago

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to... Full story

Yahoo Finance • 5 months ago

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its... Full story

Yahoo Finance • 6 months ago

Liquidia Corporation to Host R&D Day in New York City on October 28, 2025

MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Res... Full story

Yahoo Finance • 7 months ago

Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares?

Arquitos Capital Management, an investment management firm, released its second-quarter 2025 investor letter. During the period, the fund delivered a net return of 13.1%, bringing year-to-date gains to an impressive 28.8% as of June 30, 20... Full story

Yahoo Finance • 7 months ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 7 months ago

Why United Therapeutics Catapulted 38%, Pulling Insmed, Liquidia With It

United Therapeutics stock catapulted Tuesday, pulling shares of rivals Insmed and Liquidia higher, on positive test results in IPF. Continue Reading View Comments... Full story

Yahoo Finance • 7 months ago

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat... Full story